Lyrica Withdrawal & Tapering Guide
pregabalin
Boxed Warning
Respiratory depression risk when used with CNS depressants, particularly opioids. Increased risk of suicidal thoughts and behavior (anticonvulsant class warning).
In short
Lyrica (pregabalin) is a Gabapentinoid with a half-life of 6 hours. Linear absorption unlike gabapentin.
- Class
- Gabapentinoid
- Half-life
- 6 hours
- Common doses
- 25mg, 50mg, 75mg, 150mg, 300mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Pregabalin is a gabapentinoid approved for neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunctive), and spinal cord injury neuropathic pain. It is a Schedule V controlled substance due to abuse potential.
25mg, 50mg, 75mg, 150mg, 300mg
Capsules: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg; Oral solution: 20mg/mL; Extended-release tablets (Lyrica CR): 82.5mg, 165mg, 330mg
Category C (risk cannot be ruled out)
Mechanism of Action
Binds potently to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Similar mechanism to gabapentin but with 6-fold higher binding affinity. Does not bind GABA receptors.
Taper Notes
Linear absorption unlike gabapentin. Short half-life requires slow taper. Capsules can be opened for precise dosing.
Hyperbolic Tapering Guidance
Linear pharmacokinetics but short half-life. Gradual reduction essential. Capsule contents can be weighed for precise reductions.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Opioids — increased risk of respiratory depression and sedation
- CNS depressants (benzodiazepines, alcohol, barbiturates) — additive sedation and respiratory depression
- ACE inhibitors — pregabalin may increase risk of angioedema
Food Interactions
- Food reduces peak concentration but does not affect total absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to pregabalin (angioedema and hypersensitivity reactions reported)
Toxicity
Dizziness and somnolence most common. Respiratory depression with CNS depressants/opioids. Physical dependence with chronic use. Euphoria/misuse potential (Schedule V). Suicidal ideation (anticonvulsant class warning). Angioedema rarely reported.
Pharmacokinetics
ADME Profile
Rapidly absorbed with linear, dose-proportional pharmacokinetics (unlike gabapentin). Bioavailability ≥90%. Tmax ~1.5 hours. Food decreases Cmax by ~25% and delays Tmax but does not reduce total absorption.
~0.5 L/kg
Negligible metabolism in humans (<2% of dose). No CYP involvement. N-methylated metabolite is the only identified metabolite.
Renal (~90% excreted unchanged). Clearance proportional to creatinine clearance.
Not significantly bound to plasma proteins
~67–80 mL/min (renal clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Gabapentinoid medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 75 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (75 mg start) |
|---|---|---|
| Start | 100% | 75 mg |
| Step 1 | 90% | 67.5 mg |
| Step 2 | 81% | 60.8 mg |
| Step 3 | 73% | 54.7 mg |
| Step 4 | 66% | 49.2 mg |
| Step 5 | 59% | 44.3 mg |
| Step 6 | 53% | 39.9 mg |
| Step 7 | 48% | 35.9 mg |
| Step 8 | 43% | 32.3 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Lyrica, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Lyrica
What are the withdrawal symptoms of Lyrica (pregabalin)?
Common withdrawal symptoms of Lyrica (pregabalin) include: anxiety, insomnia, sweating, nausea, headache, seizure risk. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Lyrica (pregabalin)?
Linear absorption unlike gabapentin. Short half-life requires slow taper. Capsules can be opened for precise dosing. Linear pharmacokinetics but short half-life. Gradual reduction essential. Capsule contents can be weighed for precise reductions.
Can I stop Lyrica cold turkey?
Stopping Lyrica abruptly is not recommended. Its half-life is 6 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Lyrica stay in your system?
Lyrica (pregabalin) has a half-life of 6 hours. A drug is mostly cleared after about five half-lives, so Lyrica is largely out of the body about 30 hours after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Recent discussions about Lyrica
What members tapering Lyrica are asking and reporting right now. Personal experience, not medical advice.
Sources & References
Lyrica (pregabalin) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms
- Royal College of Psychiatrists — Pregabalin and gabapentin — UK clinical guidance on pregabalin and gabapentin prescribing
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.